Targeting Interferon‐Gamma (IFN‐γ)‐Related Signalling Pathways in Inflammatory Bowel Disease: Emerging Inhibitors and Therapeutic Advances
Mediators of Inflammation · 2025
DOI: 10.1155/mi/3181200 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Mediators of Inflammation, 2025. Verfasst von Md Mizanur Rahaman und 2 weiteren Autor:innen. Beteiligte Einrichtung: Biomedical Sciences and Molecular Biology, College of Medicine and Dentistry, James Cook University, Townsville, Queensland 4811, Australia. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Interferon-gamma. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 148 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Australian Government.
Abstract (Originalsprache)
Inflammatory bowel disease (IBD) encompasses a group of chronic and relapsing inflammatory disorders of the gastrointestinal tract, driven by a multifaceted interplay between genetic predisposition, environmental factors and dysregulated immune responses. Central to its immunopathogenesis is the aberrant activation of pro‐inflammatory cytokine networks, among which interferon‐gamma (IFN‐γ) has been increasingly recognised as a critical mediator of mucosal damage and disease perpetuation. IFN‐γ exerts pleiotropic effects on both innate and adaptive immune compartments, orchestrating a pathogenic immune milieu that disrupts intestinal epithelial integrity and sustains chronic inflammation. Recent therapeutic advances have focused on the modulation of IFN‐γ signalling as a targeted approach to restoring intestinal homeostasis. A growing repertoire of IFN‐γ inhibitors—including neutralising monoclonal antibodies (MAbs), small‐molecule Janus kinase (JAK) inhibitors and bioactive phytochemicals—are being explored for their capacity to attenuate IFN‐γ‐driven inflammatory cascades. These agents offer distinct mechanistic profiles, targeting various nodes of the IFN‐γ axis, and hold significant promise for addressing therapeutic gaps in refractory IBD. This review provides a comprehensive evaluation of emerging IFN‐γ‐targeted therapies, detailing their mechanisms of action, preclinical and clinical efficacy and translational potential. By elucidating the therapeutic landscape of IFN‐γ modulation, this study aims to inform the development of more effective and personalised treatment strategies for patients with IBD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Biomedical Sciences and Molecular Biology, College of Medicine and Dentistry, James Cook University, Townsville, Queensland 4811, Australia.
- Australian Institute of Tropical Health and Medicine, James Cook University, Townsville, Queensland 4811, Australia.
- College of Science and Engineering, James Cook University, Nguma Bada Campus, McGregor Road, Smithfield, Cairns, Queensland 4878, Australia.
- Australian Institute of Tropical Health and Medicine, James Cook University, Nguma Bada Campus, McGregor Road, Smithfield, Cairns, Queensland 4878, Australia.
- Department of Microbiology, Anatomy, Physiology and Pharmacology, School of Agriculture, Biomedicine and Environment, La Trobe University, Melbourne, Victoria 3086, Australia.
ORCID-Profile: Md Mizanur Rahaman, Subir Sarker
Förderung
- Australian Government
Zitieren
APA
Rahaman, M. M., Wangchuk, P., & Sarker, S. (2025). Targeting Interferon‐Gamma (IFN‐γ)‐Related Signalling Pathways in Inflammatory Bowel Disease: Emerging Inhibitors and Therapeutic Advances. Mediators of Inflammation. https://doi.org/10.1155/mi/3181200
Vancouver
Rahaman MM, Wangchuk P, Sarker S. Targeting Interferon‐Gamma (IFN‐γ)‐Related Signalling Pathways in Inflammatory Bowel Disease: Emerging Inhibitors and Therapeutic Advances. Mediators of Inflammation. 2025. doi:10.1155/mi/3181200
BibTeX
@article{Rahaman2025,
author = {Rahaman, Md Mizanur and Wangchuk, Phurpa and Sarker, Subir},
title = {Targeting Interferon‐Gamma (IFN‐γ)‐Related Signalling Pathways in Inflammatory Bowel Disease: Emerging Inhibitors and Therapeutic Advances},
journal = {Mediators of Inflammation},
year = {2025},
doi = {10.1155/mi/3181200}
}
EUVIMED